The UK medicines regulatory and approval landscape is evolving, with major reforms aimed at accelerating patient access, improving system efficiency, and strengthening the UK’s position as a competitive market for developing and launching new medicines.
The UK government continues to work toward developing its medicines regulation and general healthcare systems, with the aim of ensuring a more efficient, future-proofed and cost-effective framework. Among other efforts, a new clinical trials regulation comes into force in April 2026, and, in July 2025, a more wide-ranging decade-long reform initiative was published as a policy paper titled “10 Year Health Plan for England: Fit for the Future.”1 The overarching rationale driving these measures is the desire to position the UK as an attractive, competitive candidate for developing and launching new medicines.
The policy paper describes plans for a broad array of updates involving various aspects of the UK’s healthcare landscape, including hospital and community care, furthering the system’s digital transformation, transparency, and quality of care and innovation to drive healthcare reform.
One of the initiative’s underpinning principles is a willingness to improve how quickly new medicines are made available to patients. Among the most forward thinking proposals is enhanced collaboration and information sharing between the National Institute for Health and Care Excellence (NICE) and the Medicines and Healthcare Regulatory Agency (MHRA).
Of course, the combined review is not to be confused with the existing Innovative Licensing and Access Pathway (ILAP), which intends to accelerate time to market and facilitate patient access to novel therapies. ILAP provides applicants with access to a toolkit to support all stages of the design, development and approvals process, along with opportunities for enhanced regulatory and stakeholder input 2.
The current process stages the NICE review 90 days after MHRA marketing authorization approval. NICE are responsible for compiling the technological appraisal guidance, to assess the clinical and cost effectiveness of medicines, devices or other health-centric technologies. The goal is balancing best-possible care for patients with value for taxpayers3.
To capitalize upon the freshly expedited review process, prospective marketing authorization holders will be required to register with UK PharmaScan4 at least three years prior to MHRA marketing authorization. Coinciding with this will be an enhanced integrated scientific advice service to assist companies with clarity on evidence requirements; here, goals include more predictable timelines, a single advice meeting and integrated report. Engagement with the Scientific Advice service will remain optional but will incur a fee when utilized.
NICE is actively seeking topics to schedule on the aligned pathway to undergo real-world testing. It is anticipated that the new service will fully launch in April 2026.
It is additionally recognized that not all companies will wish to adopt this aligned pathway, especially when they are unable to meet NICE submission timelines. In such cases NICE will publish a deferral, providing full transparency on when the medicine will be evaluated following marketing authorization.
The industry has cautiously welcomed the proposals from the UK government, as well as the more expedient outcome timelines for NICE reviews. Prominent pharma manufacturing organizations such as PCI Pharma Services are generally viewing these updates as progress toward jumpstarting the UK healthcare sector through faster patient access to new medicines.
Additionally, in late 2025 the UK and US governments finalized the UK-US Economic Prosperity deal, which included a 0% tariff on pharmaceutical exports from the UK to US for at least three years. This agreement further bolstered the UK’s position as a desirable location to produce drug products intended for the US market5.
As a measure of reciprocity under the same deal, the UK government pledged to spend 25% more on innovative treatments from the US that, previously, may not have met NICE criteria for cost effectiveness. Correspondingly, the UK has secured mitigations under the United States’ ‘Most Favored Nation’ drug pricing initiative, further strengthening the UK as a priority market for early therapy launches.
These new synergies with the US also strengthen the previously implemented International Recognition Procedure (IRP)6, which allows the MHRA to take account of the expertise and decision-making of trusted regulatory partners including the US, Australia, Canada, Switzerland, Singapore, Japan and EU/EEA member states. Based on a prior assessment by one or more of these partners, MHRA can invoke the IRP to make a targeted recommendation that, ideally, facilitates faster approval and market access within the UK. The IRP is applicable to new chemical and biological active substances, generic applications, hybrid applications, biosimilar applications and new fixed product combinations.
There was understandable concern that, upon leaving the EU, the UK would be left adrift in the global pharma market. However, government entities have been diligently refining existing regulations to create a more hospitable environment to conduct clinical trials, and launch new drugs in the UK. PCI remains uniquely placed to support the biopharma industry with UK based drug product manufacturing and testing, primary and secondary packaging and supply chain management solutions for clinical studies through to commercial launch, serving the UK and global markets.